Sleep Disorders Trial, Recruiting NCT07682532 Sponsor: Medipol University Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT07682532
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Parkinson's Disease and are classified as Stage 1 on the Hoehn-Yahr scale (an early stage of the condition)
  • People who do not have difficulties with communication or language (such as aphasia)
  • People who are willing to voluntarily sign a consent form agreeing to take part in the study
  • People who do not have dementia and who score above 24 on a standard memory and thinking test (the MMSE)
  • People who live in the same home as a healthy spouse or partner
  • People who are not currently taking prebiotics, fibre supplements, probiotics, herbal products, or high-dose vitamins or minerals that could affect inflammation

Who may not be able to join:

  • People with a history of severe heart, lung, liver, or kidney failure, or who have a primary psychiatric condition, a developmental condition, or another neurological disease
  • People who take sedative or sleeping medications
  • People who consume more than 200 mg of caffeine per day (roughly equivalent to 2–3 cups of tea or 1 cup of coffee)
  • People who smoke or drink alcohol
  • People who have had surgery related to their bowel
  • People who have a long-term infectious bowel disease
  • People who were born with an abnormality of the bowel
  • People who have used probiotics, antifungal medications, or antibiotics within the last three months
  • People who have an autoimmune disease or a weakened immune system
  • People who report using alcohol or drugs within the last three months
  • People who are currently using any over-the-counter medications, supplements, foods, or drinks that may affect stress, sleep, thinking, or mood
  • People who have difficulty swallowing due to swallowing anxiety, which would prevent them from taking the study supplement
  • People receiving treatment for a gut or digestive condition diagnosed by a doctor — unless that condition is constipation, gastroparesis, gastroesophageal reflux disease, or diverticular disease (confirm with trial site)
  • People who test positive for HIV or Hepatitis B or C
  • People who currently have active inflammatory bowel disease, irritable bowel syndrome, colitis, coeliac disease, short bowel syndrome, or who have had a colostomy or colectomy, or who have gastrointestinal fistulas or strictures
  • People who have used any antibiotic within the four weeks before the study begins
  • People who use enemas or suppositories to manage constipation
  • People who already closely follow a Mediterranean diet, as determined by a score above 6 on a standard 14-item assessment tool used before the study starts

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +90 543 939 15 94

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Medipol University
Registry
ClinicalTrials.gov
Start date
2 May 2026
Est. completion
25 September 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

RBD Screening Questionnaire (RBDSQ) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov